PTPRS and lupus nephritis: a new target to reduce kidney damage in lupus
Official title: Role of PTPRS in lupus nephritis
Funded at Cedars-Sinai Medical Center · NIH-11465789 · Data updated 2026-11-12
Aims to understand how PTPRS contributes to kidney inflammation and scarring in lupus nephritis and explore targeting it to help patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cedars-Sinai Medical Center NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | September 1, 2026 |
| Project end | May 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $826,174 |
| NIH project number | 1R01DK146456-01A1 |
| Project ID | NIH-11465789 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with lupus nephritis or related autoimmune kidney conditions who could contribute tissue samples or clinical data.
✕Less likely to help
People without lupus nephritis or access to related tissue samples may not benefit directly.
What this research studies
This project will study how the protein PTPRS behaves in immune cells found in the kidneys of people with lupus nephritis. Researchers will look at how PTPRS interacts with syndecan-1 and how these signals drive inflammation and fibrosis. They will identify the molecular switches and substrates involved, and examine how this pathway affects long-term kidney damage. The work is designed to translate basic findings into potential new therapies for lupus kidney disease.
Why it matters
Potential benefit: If successful, the research could identify new therapeutic targets to reduce kidney inflammation and scarring in lupus nephritis, potentially improving remission rates and kidney outcomes.
How similar studies have gone: Previous studies have linked PTPRS pathways to immune cell regulation; this project builds on those findings with a disease-specific focus.
Where this research is happening
-
Cedars-Sinai Medical Center
Los Angeles, United States Active
Researchers
- Principal investigator: Bottini, Nunzio — Cedars-Sinai Medical Center
- Study coordinator: Bottini, Nunzio
Related research
Other NIH-funded projects on the same topics.
-
Glycoprotein urine markers that signal lupus nephritis treatment response
A novel test uses urine glycoprotein patterns to show how well lupus nephritis is responding to standard treatment.
-
Sodium’s effect on kidney B cells in lupus kidney disease
This grant explores how high sodium in the kidneys affects B cells in lupus nephritis and whether blocking a key cellular pump could reduce kidney damage.
-
Oral CD11b Activator for Lupus Nephritis
A new oral CD11b activating drug is being explored to help people with lupus nephritis by targeting immune pathways that cause kidney inflammation.
-
Objective classification of lupus nephritis using computer vision
A new computer vision tool uses deep learning to classify lupus nephritis from kidney tissue images to help doctors predict outcomes for patients with lupus.
-
AI-powered look at lupus nephritis in humans and mice
Researchers will use artificial intelligence to compare kidney tissue from people with lupus nephritis to tissue from mouse models, aiming to understand why treatments work differently in humans.
-
miR-21 and B cells in lupus: how a tiny molecule can drive autoimmunity
Aims to understand how a microRNA called miR-21 influences B cells and kidney inflammation in lupus, with the goal of finding targeted therapies for people with SLE.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.